Lipopolysaccharide-induced cytokine and chemokine expression in human carotid lesions

Journal of Vascular Research

Volumn 42, Issue 3, 2005, Pages 266-271

  Jatta, Ken ^a   Wågsäter, Dick ^a   Norgren, Lars ^b   Stenberg, Björn ^b   Sirsjö, Allan ^a  

^a ÖREBRO UNIVERSITY   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; IL 1 , 6, 8, 10; IP 10; MCP 1; MIG; RANTES; TNF

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CHEMOKINE; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VIRULENCE FACTOR; LIPOPOLYSACCHARIDE;

ARTICLE; ATHEROGENESIS; BRAIN ATHEROSCLEROSIS; CAROTID ARTERY INJURY; CELL LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; INCUBATION TIME; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; RENAL ARTERY; VIRULENCE; CAROTID ARTERY; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; DRUG EFFECT; GENETICS; METABOLISM;

CAROTID ARTERIES; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CHEMOKINES; CYTOKINES; HUMANS; LIPOPOLYSACCHARIDES; RENAL ARTERY; RNA, MESSENGER;

EID: 20644446293     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085721     Document Type: Article

References (25)

1. Burke-Gaffney A, Brooks AV, Bogle RG: Regulation of chemokine expression in atherosclerosis. Vascul Pharmacol 2002;38:283-292.
2. Haley KJ, Lilly CM, Yang JH, et al: Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: Using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 2000;102:2185-2189.
3. Plutzky J: Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001;88:10K-15K.
4. Blake GJ, Ridker PM: Inflammatory biomarkers and cardiovascular risk prediction. J Intern Med 2002;252:283-294.
5. Ostos MA, Recalde D, Zakin MM. Scott-Algara D: Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett 2002; 519:23-29.
6. Fong IW: Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ 2000;163:49-56.
7. Glass CK, Witztum JL: Atherosclerosis. The road ahead. Cell 2001;104:503-516.
8. Fiotti N, Giansante C, Ponte E, et al: Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 1999;145:51-60.
9. Mach F, Sauty A, Iarossi AS, et al: Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999;104:1041-1050.
10. Blake GJ, Ridker PM: Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-771.
11. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R: Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999;19:2364-2367.
12. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al: Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability. Circulation 2000;101:1372-1378.
13. Seino Y, Ikeda U, Ikeda M, et al: Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994;6:87-91.
14. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al: MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999;398:718-723.
15. Aiello RJ, Bourassa PA, Lindsey S, et al: Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vase Biol 1999;19:1518-1525.
16. Rus HG, Vlaicu R, Niculescu F: Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996;127:263-271.
17. Gu L, Okada Y, Clinton SK, et al: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275-281.
18. Shin WS, Szuba A, Rockson SG: The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 2002;160:91-102.
19. Memon RA, Staprans I, Noor M, et al: Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 2000;20:1536-1542.
20. Streblow DN, Orloff SL, Nelson JA: Do pathogens accelerate atherosclerosis? J Nutr 2001;131:27988-28045.
21. Grayston JT: Antibiotic treatment of atherosclerotic cardiovascular disease. Circulation 2003;107:1228-1230.
22. Rice JB, Stoll LL, Li WG, et al: Low-level endotoxin induces potent inflammatory activation of human blood vessels: Inhibition by statins. Arterioscler Thromb Vasc Biol 2003;23:1576-1582.
23. Scheeter AD, Berman AB, Taubman MB: Chemokine receptors in vascular smooth muscle. Microcirculation 2003;10:265-272.
24. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 2001;2:135-145.
25. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ: Expression of toll-like receptors in human atherosclerotic lesions: A possible pathway for plaque activation. Circulation 2002;105:1158-1161.